Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 3Gastrointestinal 2Other hematologic neoplasm 1Gynecologic 1Genitourinary 1Endocrine 1Dermatologic 1Breast 1

Conditions

Leukemia 1Hematologic Neoplasms 1Graft vs Host Disease 1Depression 1

Interventions

Cytarabine 905Cyclophosphamide 899fludarabine 525venetoclax 489fludarabine phosphate 468Azacitidine 460Rituximab 431Methotrexate 419Etoposide 320Filgrastim 299Busulfan 296Dexamethasone 286Vincristine 285Daunorubicin 283Peripheral Blood Stem Cell Transplantation 258Whole-Body Irradiation 243Mycophenolic Acid 232Decitabine 230Granulocyte Colony-Stimulating Factor 227Tacrolimus 220Imatinib Mesylate 211Idarubicin 205Melphalan 202Cyclosporine 182Doxorubicin 177Radiotherapy 169Prednisone 164Dasatinib 163Mitoxantrone 161Lenalidomide 160

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Health × Other hematologic neoplasm × Clear all
NCT02976558 2019-12-18

TriCAM

University of Erlangen-Nürnberg Medical School

Phase NA Terminated
104 enrolled
Other hematologic neoplasm

Depression, Graft vs Host Disease, Leukemia, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡